Key result
High hs-cTnI links to acute heart failure mortality primarily through inflammation, congestion, and renal impairment.
Why the study?
Cardiac troponin elevation strongly predicts mortality in acute heart failure, but the mechanisms underlying its release beyond acute myocardial ischaemia are not fully understood.
Does high-sensitivity cardiac troponin I independently predict 180-day mortality in patients hospitalized for acute heart failure without acute coronary syndrome?
Cohort (n=431)
Does high-sensitivity cardiac troponin I independently predict 180-day mortality in patients hospitalized for acute heart failure without acute coronary syndrome?
In acute heart failure, the association between circulating troponin and mortality is largely explained by systemic inflammation, congestion, and renal impairment, suggesting troponin reflects disease severity rather than providing independent prognostic information.
Answers are grounded in this paper and cite their sources.
hs-cTnI should not yet inform independent risk stratification in acute HF; hypothesis-generating regarding mediation by inflammation, congestion, and renal function.
AIMS Elevation of cardiac troponin (cTn) is a strong predictor of mortality in acute heart failure (AHF), but the mechanisms underlying cTn release are not fully understood. Beyond acute myocardial ischaemia, ventricular stretch, systemic inflammation and renal dysfunction may contribute. We evaluated the prognostic association between high–sensitivity cardiac troponin I (hs–cTnI) and 180–day mortality in AHF, considering congestion, inflammation and renal function as potential mediators. Methods We enrolled patients hospitalized for AHF without acute coronary syndrome. At admission, congestion, inflammation and renal function were assessed using brain natriuretic peptide (BNP, pg/mL), high–sensitivity C–reactive protein (hs–CRP, mg/L) and estimated glomerular filtration rate (GFR, mL/min), respectively. After confirming associations of these variables with hs–cTnI and mortality, we performed parallel mediation analysis to quantify mediation effects. Results Among 431 patients (79±10 years; 51% men), 180–day mortality was 36%. Admission hs–cTnI levels did not differ between patients with and without chronic coronary artery disease and correlated with BNP (r=0.38), hs–CRP (r=0.21) and GFR (r=−0.23). In multiple regression, hs–CRP, BNP and GFR explained 18% of hs–cTnI variability. In univariable Cox models, hs–cTnI, hs–CRP, BNP and GFR predicted all–cause death. The hs–cTnI–mortality association was partially mediated by inflammation, congestion and renal function, accounting for 23%, 16% and 23% of the total effect, respectively; together these mediators explained 62% of the association. In multivariable Cox models, ln(hs–CRP) (HR 1.21, 95% CI 1.08–1.37), ln(BNP) (HR 1.37, 95% CI 1.09–1.74) and GFR (HR 0.99, 95% CI 0.98–1.00) remained independently associated with mortality, whereas ln(hs–cTnI) did not (HR 1.07, 95% CI 0.97–1.17). Conclusions In AHF, circulating troponin is associated with mortality, but this relationship is largely explained by systemic inflammation, congestion and renal impairment. Troponin appears to reflect disease severity rather than provide independent prognostic information.
No takes yet. Share an insight, caveat, or question.
Barnaba et al. (2026) conducted a cohort in Acute heart failure (n=431). High-sensitivity cardiac troponin I (hs-cTnI) was evaluated on 180-day mortality (HR 1.07, 95% CI 0.97-1.17). In acute heart failure, the association between high-sensitivity cardiac troponin I and 180-day mortality is largely mediated by inflammation, congestion, and renal impairment (HR 1.07; 95% CI 0.97-1.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: